Press Releases
- Teva and Active Biotech Announce Discontinuation of Higher Doses of Laquinimod in Two Multiple Sclerosis Trials January 4, 2016 15:00 (CET)
- Active Biotech's election committee appointed November 23, 2015 08:35 (CET)
- Active Biotech's election committee appointed November 23, 2015 08:30 (CET)
- Active Biotech AB Interim report January - September 2015 November 6, 2015 08:32 (CET)
- Active Biotech AB Interim report January - September 2015 November 6, 2015 08:30 (CET)
- Active Biotech's partner Teva presents data on laquinimod for the treatment of multiple sclerosis at 31st ECTRIMS Congress October 6, 2015 14:11 (CEST)
- Active Biotech's partner Teva presents data on laquinimod for the treatment of multiple sclerosis at 31st ECTRIMS Congress October 6, 2015 14:00 (CEST)
- Final results from Active Biotech's 10TASQ10 Phase 3 study of tasquinimod presented at the ECC conference September 28, 2015 08:39 (CEST)
- Final results from Active Biotech's 10TASQ10 Phase 3 study of tasquinimod presented at the ECC conference September 28, 2015 08:30 (CEST)
- Active Biotech AB Interim report January - June 2015 August 7, 2015 08:38 (CEST)